Allergan, TARGET PharmaSolutions partner on ongoing NASH study

Allergan will partner with TARGET PharmaSolutions on its TARGET-NASH study, a five-year longitudinal observational study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children, according to a press release.

“TARGET-NASH is critical for the scientific and regulatory community as we prepare for new agents for the treatment of NASH,” Arun Sanyal, MD, co-chair of the TARGET-NASH Steering Committee, said in the release. “In the immediate term, it will give us a critical understanding of NASH diagnosis and management in the real world across multiple populations. In the longer term, it is the perfect platform to have a deep understanding of the safety and effectiveness of these new agents across populations not included or underrepresented in phase 3 clinical trials.”

The TARGET-NASH study is based on the successful HCV-TARGET study and researchers designed it to facilitate greater understanding of the impact of NAFLD and NASH and future treatment options. The first patient enrolled on Aug. 1, 2016, and since then the study has grown to comprise 15,000 adult and adolescent patients.

Reference: www.allergan.com